Biocytogen’s wholly owned subsidiary Eucure Biopharma today announced that the company will present two phase II clinical studies of YH003, a humanized anti-CD40 agonistic monoclonal antibody, at the American Society of Clinical Oncology (ASCO) annual meeting, taking place in Chicago, US, from May 31-June 4, 2024.
Poster Session:
Clinical Trial Registration Number: NCT05031494
Abstract Number: 4146
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track: Pancreatic Cancer - Advanced/Metastatic Disease
Poster Bd #: 126
Date and Time: 13:30-16:30 CDT, June 1, 2024
Location: Hall A
Publication Only:
Clinical Trial Registration Number: NCT05420324
Abstract Number: e21520
Track: Melanoma/Skin Cancers
Sub Track: Advanced/Metastatic Disease
About YH003
YH003 is a humanized IgG2 agonistic anti-CD40 monoclonal antibody independently developed by Biocytogen/Eucure Biopharma. Based on the safety, efficacy, and PK data from the previous phase I study, the recommended phase II dose (RP2D) of YH003 was identified as 0.3 mg/kg. The combination of YH003 and Toripalimab has shown encouraging anti-tumor activity in patients with advanced solid tumors.
Preclinically, YH003, whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, demonstrated strong anti-tumor effects in multiple tumor models in Biocytogen’s humanized CD40 mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.
At AACR2024, our collaborator Syncromune revealed initial clinical data of SYNC-T SV-102, which includes YH003 and our clinical-stage CTLA-4 monoclonal antibody YH001. SYNC-T SV-102 demonstrated a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Learn More About SYNC-T SV-102
Interested in learning more about our YH003 mAb? Contact us today for partnership opportunities!
